TMCnet News
UCB Group - SWOT Analysis - Aarkstore EnterpriseUCB Group - SWOT Analysis company profile is the essential source for top-level company data and information. UCB Group - SWOT Analysis examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy. UCB is a global biopharmaceutical company. The company focuses on severe diseases in the fields of central nervous system (including epilepsy), inflammation (including allergy), and oncology. It has more than 140 subsidiaries in Europe, North and South America, and Asia. The company is headquartered in Brussels, Belgium and employs more than 12,100 people. The company recorded revenues of E3,626 million (approximately $5,340.6 million) during the fiscal year ended December 2007, an increase of 42.1% over 2006. The operating profit of the company was E344 million (approximately $506.7 million) during fiscal year 2007, a decrease of 39.8% over 2006. The net profit was E161 million (approximately $237.1 million) in fiscal year 2007, a decrease of 56.1% over 2006. Scope of the Report Provides all the crucial information on UCB Group required for business and competitor intelligence needs Contains a study of the major internal and external factors affecting UCB Group in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams of UCB Group Data is supplemented with details on UCB Group history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available statement from UCB Group Reasons to Purchase Support sales activities by understanding your customers’ businesses better Qualify prospective partners and suppliers Keep fully up to date on your competitors’ business structure, strategy and prospects Obtain the most up to date company information available For more information, please visit : http://www.aarkstore.com/reports/UCB-Group-SWOT-Analysis-26876.html As a community-building service, TMCnet allows user submitted content which is not always proofed by TMCnet editors. If you feel this entry is of inferior quality or wish to report it for some reason, please forward the URL to "webedit [AT] tmcnet [DOT] com" with your comments. |